Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3CNS 2Breast 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Neoplasm Metastasis 1Glioblastoma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Has results × etirinotecan pegol × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01773109 2020-04-03

Etirinotecan Pegol (NKTR-102) in NSCLC

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
40 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01876446 2020-03-17

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Completed
38 enrolled 16 charts
Thoracic

Small Cell Lung Carcinoma

NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡